Tag: Coloplast
Cath changes: Stakeholders anxious about next steps
April 4, 2025Theresa Flaherty, Managing Editor
WASHINGTON – As the PDAC continues to ready its roll-out of new HCPCS codes for certain catheters, the $1 million question for stakeholders is still, what will be in the local coverage determination?
The PDAC is currently working with manufacturers to determine if their products qualify for one of the new codes (A4295, A4296 and A4297 are brand new, while A4351 and A4352 are revised and A4353 remains unchanged). The PDAC is expected to identify the products that qualify under the new...
In brief: Reimbursement relief, MA guardrails, Numotion pilot
December 6, 2024HME News Staff
WASHINGTON – More than 30 leading patient advocacy organizations have weighed in with congressional leadership to support including provisions from H.R. 5555 and S. 1294 in any legislative package that moves before the end of the year, AAHomecare reports.
In a Dec. 2 letter from the ITEM Coalition, the groups assert that the expiration of 75/25 blended Medicare reimbursement rates on Jan. 1, 2024, has resulted in a “crushing blow to DMEPOS suppliers and providers, threatening...
Coloplast divests skin care biz
December 5, 2024HME News Staff
MINNEAPOLIS – Coloplast has divested its core Skin Care business to focus on its Advanced Wound Care business. Revenue from the core Skin Care business amounted to around DKK 400 million in FY 2023/24, with an operating profitability level significantly below the group EBIT margin. Coloplast’s FY 2024/25 financial guidance of organic revenue growth of 8% to 9% and an EBIT margin before special items of around 28% is unchanged and already includes the divestment. This simplification of...
Coloplast sees organic growth
May 8, 2024HME News Staff
MINNEAPOLIS – Coloplast saw 8% organic growth in its second quarter ended March 31, 2024. Organic growth rates by business area were ostomy care 7%, continence care 8%, advanced wound care 8% and interventional urology 5%. “We deliver a solid second quarter with 8% organic growth and an EBIT margin of 27%, which is in line with our financial guidance,” said Kristian Villumsen, president and CEO, in an interim financial report. “I would like to highlight a strong Q2 performance...
BOC taps Jason Morin for board
February 1, 2024HME News Staff
OWINGS MILLS, Md. – The Board of Certification/Accreditation (BOC) board of directors has appointed Jason R. Morin as a public member. Morin, currently senior manager of payer relations for Coloplast, is an executive leader with more than 20 years of experience in optimizing reimbursement operations and third-party payer relationships in the home medical equipment sector. “We are pleased to welcome Jason to the board,” says BOC Board Chair Cameron Stewart, BOCO, BOCP. “His...
Patient access: Reach out, speak up
August 9, 2023Kathryn Vaughn
Q. When is it time to challenge the status quo?
A. We cringe when we hear the phrase, “We’ve always done it that way.” Leaders know that change is constant and reliance on outdated methods can prove fatal to a business. However, when it comes to advocacy, many ask “What’s the use, it’ll never change?” It is easy to understand how people come to feel this way, as our industry is often overlooked and undervalued. However, the reality is that...
In brief: ADS taps Bill Mixon as CEO, Coloplast buys Kerecis
July 12, 2023HME News Staff
CARLSBAD, Calif. - Advanced Diabetes Supply has appointed Bill Mixon, who previously led National Seating & Mobility, as its CEO.
The announcement follows the transition of the company’s co-founders and co-CEOs, Mark Howard and Tim Cady, to strategic advisory roles as members of the board of directors.
“Bill has provided valuable insight and support to the ADS leadership team as a board member for the last two years,” said Jeffrey Abramoff, a partner at Court Square,...
Coloplast expands into biologics wound care segment
July 10, 2023HME News Staff
MINNEAPOLIS – Coloplast has signed an agreement to buy Kerecis, a biotech company based in Iceland that is pioneering the use of fish skin in the regenerative medicine market, for up to $1.3 billion.
Coloplast will pay $1.2 billion upfront on a cash and debt-free basis and will pay up to a $100 million earnout dependent on financial performance in fiscal year 2023-24.
“The advanced wound care market holds significant untapped potential, and today Coloplast is only present...
Patient Access: Identify gaps in access
July 10, 2023Kathryn Vaughn
Q. How can HME providers impact patient access?
A. In this post-pandemic world, patient access to home medical equipment continues to be threatened by increasing costs. Significant inflation (7.2% in 2022), shipping and supply chain costs, coupled with stagnant reimbursement, may pose challenges for providers to supply the high quality HME preferred by patients and prescribed by clinicians. Providers may assume an active role in improving patient access by actively reviewing payer contracts...
Patient Access: Know value of support programs
June 7, 2023Kathryn Vaughn
Q. How are consumer support programs beneficial to users and HMEs?
A. Manufacturer consumer support programs are free and often brand agnostic for individuals, health care professionals and HMEs. Trained advisers encourage compliance to practice guidelines for managing chronic health conditions. Resources include condition specific education, advice on lifestyle modification, product troubleshooting and tools to be successful. Typically, programs also provide product samples and help connect...